Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -
Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -
Immuneering | 8-K:Immuneering 公佈 2023 年第四季度和全年財務業績並提供業務更新-IMM-1-104 1/2a 階段試驗第 1 階段的重點數據,預計於 2024 年 3 月發佈-